Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Frontiergate Biotechnology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, DUFFY, BRADLEY. The prosecution is focused within 1 distinct art unit, which is typical for specialized biotechnology applications. This 1 pending office action represents the company's current active pursuit of patent protection in this field.
The busiest examiner, DUFFY, BRADLEY, is responsible for 1 busiest examiner pending action. This matches the company's total of 1 pending office action. With only 1 distinct examiner and 1 distinct art unit, the prosecution is highly centralized. Practitioners can focus their efforts on the specific examination style of this single individual. The technical nature of the 1 distinct art unit will likely dictate the complexity of the arguments required. Because the entire pending portfolio is with DUFFY, BRADLEY, the company's immediate success in the Biotechnology & Pharmaceuticals area depends on this single examiner's review. This streamlined structure allows for a very focused and consistent prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19029764 | ALLOGENEIC DENDRITIC CELL (alloDC) TUMOR VACCINE, AND PREPARATION METHOD AND USE THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19029764 | ALLOGENEIC DENDRITIC CELL (alloDC) TUMOR VACCINE, AND PREPARATION METHOD AND USE THEREOF | DUFFY, BRADLEY | 1643 | §102DP | Non-Final OA | — | Pending | Jan 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial